Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Buckley

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Latent class analysis of symptoms across schizophrenia, schizoaffective disorder, and bipolar I disorderDana M Lapato, Roseann E Peterson, Eric D Achtyes, et al.
Schizophrenia Research|July 18, 2020
Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizophrenia, and schizoaffective disorderMilena Y Gotra, Scot K Hill, Elliot S Gershon, et al.
Schizophrenia Research|October 24, 2017
Genetic analysis of deep phenotyping projects in common disordersElliot S Gershon, Godfrey Pearlson, Matcheri S Keshavan, et al.
Schizophrenia Bulletin|May 30, 2014
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyPeter F Buckley, Nina R Schooler, Donald C Goff, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon, Jan Volavka, Virginia Stauffer, et al.
Schizophrenia Research|January 12, 2023
Longitudinal study of inflammation and relapse in schizophreniaBrian J Miller, Henrique Lemos, Nina R Schooler, et al.
Schizophrenia Research|July 24, 2017
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?Anilkumar Pillai, Nina R Schooler, Diya Peter, et al.
The Journal of Clinical Psychiatry|December 7, 2007
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore, Robert W Buchanan, Peter F Buckley, et al.
The Journal of Clinical Psychiatry|June 13, 2012
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trialRichard S E Keefe, Sophia Vinogradov, Alice Medalia, et al.
The Journal of Clinical Psychiatry|May 4, 2004
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller, Catherine S Hall, Robert W Buchanan, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Latent class analysis of symptoms across schizophrenia, schizoaffective disorder, and bipolar I disorderDana M Lapato, Roseann E Peterson, Eric D Achtyes, et al.
Schizophrenia Research|July 18, 2020
Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizophrenia, and schizoaffective disorderMilena Y Gotra, Scot K Hill, Elliot S Gershon, et al.
Schizophrenia Research|October 24, 2017
Genetic analysis of deep phenotyping projects in common disordersElliot S Gershon, Godfrey Pearlson, Matcheri S Keshavan, et al.
Schizophrenia Bulletin|May 30, 2014
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyPeter F Buckley, Nina R Schooler, Donald C Goff, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose studyBruce J Kinon, Jan Volavka, Virginia Stauffer, et al.
Schizophrenia Research|January 12, 2023
Longitudinal study of inflammation and relapse in schizophreniaBrian J Miller, Henrique Lemos, Nina R Schooler, et al.
Schizophrenia Research|July 24, 2017
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?Anilkumar Pillai, Nina R Schooler, Diya Peter, et al.
The Journal of Clinical Psychiatry|December 7, 2007
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 updateTroy A Moore, Robert W Buchanan, Peter F Buckley, et al.
The Journal of Clinical Psychiatry|June 13, 2012
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trialRichard S E Keefe, Sophia Vinogradov, Alice Medalia, et al.
The Journal of Clinical Psychiatry|May 4, 2004
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateAlexander L Miller, Catherine S Hall, Robert W Buchanan, et al.
Pageof 18